Acute Myeloid Leukemia With Gene Mutations (DBCOND0076274)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT03588078	Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine	Azacitidine Eprenetapopt	treatment	1 / 2	unknown_status
NCT01904136	Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia	Cyclophosphamide Fludarabine Mechlorethamine Mycophenolate mofetil Natural Killer Cell Tacrolimus	treatment	1 / 2	completed
NCT03333486	Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer	Cyclophosphamide Fludarabine	treatment	2	active_not_recruiting
NCT03746912	Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib	Quizartinib	Not Available	Not Available	no_longer_available
NCT04493164	CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	Cytarabine Daunorubicin Ivosidenib	treatment	2	recruiting
NCT02723435	Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant	Midostaurin	treatment	2	withdrawn
NCT02634827	Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation	Decitabine Midostaurin	treatment	2	terminated
NCT01760655	Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies	1,4-Butanediol Busulfan Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus Therapeutic allogeneic lymphocytes	treatment	2	completed